Videos

Study results indicated that the small molecule HIF-2α inhibitor MK-6482 induced positive results in patients with certain Von Hippel-Lindau disease–associated solid tumors.

The myeloma expert discussed the importance of sustained MRD negativity for patients with multiple myeloma treated with daratumumab (Darzalex).

The medical oncologist at the Mayo Clinic in Phoenix, spoke about the progress seen in gastrointestinal cancer research in 2020, as well as what improvements he hopes will occur in 2021.

Study results revealed the impact of a rurally focused telemedicine program on patient outcomes.

Short discussed currently available assays for MRD detection, blinatumomab treatment, and other implications from an ALL study presented at the 2020 ASH Annual Meeting.

Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.

A study of the effect of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab indicated that hypogammaglobulinemia was nearly universal during treatment, suggesting a role for IVIG.

Vikram Narayan, MD, expanded on his data regarding nadofaragene and NMIBC published at this year’s SUO Meeting.

The leukemia expert offered an overview of agents approved by the FDA this year.

Extended follow up and preliminary findings from an extension cohort of the GO29365 study of polatuzumab vedotin (Polivy) for patients with diffuse large B-cell lymphoma confirmed earlier reports of efficacy and safety, and demonstrated continued deepening responses.

Dan Pollyea, MD discusses the response rate and overall survival of venetoclax for patients with acute myeloid leukemia with IDH mutations.

Declan Murphy discusses the accuracy findings from the proPSMA study presented at the 2020 SUO Meeting.

Study results indicated that MK-6482 demonstrated durable efficacy in patients with Von Hippel-Lindau disease-associated clear cell renal cell carcinoma, pancreatic lesions, and hemangioblastomas by targeting the underlying pathophysiology of the disease.

The director of clinical research in the Center for Cancer Care at White Plains Hospital explained the design of the study which evaluated diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.

The expert from the Levine Cancer Institute discussed the findings from an updated analysis of the phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.

The Emory University Winship Cancer Institute expert discussed FDA approvals and other treatment advances that occurred this year.

The study was designed to determine the impact of a rurally focused telemedicine program on patient outcomes.

Short summarized the NGS-based MRD findings from his ALL study presented at the 2020 ASH Annual Meeting.

Narayan expanded on the other studies he contributed to from SUO investigating nadofaragene for patients with NMIBC.

Ghobadi explained an interesting correlation found in the results of his study presented at the 2020 ASH Annual Meeting & Exposition.

Wolf discussed the decisions to change therapy based on the MRD status of patients with multiple myeloma.

The expert in urologic oncology spoke about the advancements made in 2020, as well as areas of prostate cancer care which he believes remain to be improved.

Plinabulin in combination with pegfilgrastim reduced the incidence of chemotherapy-induced neutropenia, compared with pegfilgrastim alone, in patients with breast cancer undergoing chemotherapy with docetaxel, doxorubicin, and cyclophosphamide.

Clinical researcher Lisa La discussed advancements in multiple myeloma research and where she hopes the field continues to expand.

With the rise of precision oncology, genomic profiling is growing in its utility to support clinical decision making. Lung cancer experts can use this resource to guide therapy selection in NSCLC. Learning more about advancements in this space can improve patient outcomes and advance the field of precision oncology.

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed which patient groups he believes require more attention.

Pollyea discussed the rationale behind a study of venetoclax and azacitidine for patients with acute myeloid leukemia with IDH mutations

The ongoing GO29365 study of combination regimens containing polatuzumab vedotin (Polivy) for patients with relapsed or refractory diffuse large B-cell lymphoma added an additional 106 patients to confirm preliminary findings of safety and efficacy.

At the 2020 SUO Meeting, Vikram M. Narayan, MD, spoke about the preliminary finds of his work with nadofaragene firadenovec.